Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Enzyme characteristics of recombinant poly(ADP-ribose) polymerases-1 of rat and human origin mirror the correlation between cellular poly(ADP-ribosyl)ation capacity and species-specific life span

(2010) Sascha Beneke et al.   MECHANISMS OF AGEING AND DEVELOPMENT

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

(2009) T Zaremba et al.   BRITISH JOURNAL OF CANCER

Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity

(2009) D. Melisi et al.   CLINICAL CANCER RESEARCH

Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke

(2009) Mike Yuan et al.   EXPERIMENTAL NEUROLOGY

Poly (ADP-ribose) polymerase-1 initiated neuronal cell death pathway—do androgens matter?

(2009) K. Vagnerova et al.   NEUROSCIENCE

Association between Polymorphisms in DNA Base Excision Repair Genes XRCC1, APE1, and ADPRT and Differentiated Thyroid Carcinoma

(2008) F.-Y. Chiang et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH